Recently, the official website of the National Medical Products Administration of China (NMPA) showed that the injectable solution of Letermovir developed by Nanjing Zhengda Tianqing, a subsidiary of Sino Biopharm, has obtained marketing approval, making it the first generic drug in the country. Letermovir tablets and injections were first approved for marketing by the FDA in the usa in 2017, under the brand name Prevymis, which is a highly anticipated new drug for cytomegalovirus (CMV). Currently, Letermovir-related formulations have been marketed in nearly 20 countries and regions including the usa, europe, and japan.